Skip to main content
S&P 5007,657.59-1.28%DOW52,721.08-0.26%NASDAQ26,101.66-2.25%BTC$81,479.00-3.49%ETH$2,393.89-4.55%GOLD$4,069.10-1.95%OIL$98.20+1.08%
Smart Investors Daily
SID Premium
IN

NASDAQ · INKT

MiNK Therapeutics, Inc.

Healthcare · Biotechnology

$10.62

Down-$0.17 (-1.60%)

Updated Oct 22, 2026, 3:48 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
58.3M
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
$8.48 – $16.93
Volume
18.5K
Avg. volume
28.08K

Price performance · INKT

INKT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

INKT closed at $10.62 after 21 trading sessions, down 14.01% for the selected period.

Last close
$10.62
Period change
-14.01%
Period low
$9.41
Period high
$12.73
Daily close
View OHLC price history
INKT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$9.80$10.99$9.80$10.6218.5K
Oct 20, 2026$9.31$9.97$9.19$9.868.44K
Oct 19, 2026$9.61$9.68$9.25$9.5614.15K
Oct 16, 2026$9.87$10.10$9.38$9.4113.63K
Oct 15, 2026$10.35$10.35$9.9337$9.9410.1K
Oct 14, 2026$10.17$10.35$10.09$10.356.02K
Oct 13, 2026$10.44$10.65$10.12$10.237.17K
Oct 12, 2026$10.90$11.2357$10.36$10.5318.78K
Oct 9, 2026$10.96$10.96$10.6801$10.7216.98K
Oct 8, 2026$11.5627$11.5627$10.96$11.0010.58K
Oct 7, 2026$11.63$11.63$11.32$11.4213.81K
Oct 6, 2026$12.11$12.20$11.63$11.7033.08K
Oct 5, 2026$12.51$12.8346$12.10$12.2028.58K
Oct 2, 2026$12.72$12.72$12.10$12.4448.97K
Oct 1, 2026$12.71$12.96$12.49$12.7326.68K
Sep 30, 2026$12.62$12.98$12.19$12.5561.14K
Sep 29, 2026$12.18$12.5908$12.0901$12.2621.96K
Sep 28, 2026$11.82$12.44$11.715$12.1113.75K
Sep 25, 2026$12.00$12.46$11.70$12.1811.49K
Sep 24, 2026$12.36$12.42$11.7461$12.309.98K
Sep 23, 2026$12.50$12.50$11.6801$12.3514.81K

Latest INKT news

The latest Smart Investors Daily articles mentioning INKT.

Stock researchCompany · Overview

INKT research

Overview

Company profile and research snapshot.

Company profile

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.00
Implied upside
—
Analysts
—
INKT recent ratings
DateFirmRatingTarget
Oct 21, 2026B. Riley SecuritiesBuy—
May 18, 2026HC Wainwright & Co.Buy—
Apr 1, 2026HC Wainwright & Co.Buy—
Aug 15, 2025HC Wainwright & Co.Buy—
Jul 15, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to res

Yahoo · Sep 30, 2026

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invaria

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By